Search

BioCryst Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

8.53 0.24

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.51

Max

8.61

Belangrijke statistieken

By Trading Economics

Inkomsten

800M

78M

Verkoop

62M

218M

K/W

Sectorgemiddelde

7.603

55.725

EPS

0.3

Winstmarge

35.92

Werknemers

435

EBITDA

799M

99M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+135.42% upside

Dividenden

By Acuity

Volgende Winsten

2 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-686K

2.2B

Vorige openingsprijs

8.29

Vorige sluitingsprijs

8.53

Nieuwssentiment

By Acuity

50%

50%

113 / 339 Rangschikking in Healthcare

BioCryst Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

25 sep 2026, 19:25 UTC

BioCryst Pharmaceuticals Inc shares are experiencing a modest increase, having reached a peak earlier in the session before settling slightly higher.

24 sep 2026, 23:25 UTC

BioCryst Pharmaceuticals Inc declined in after-market trading, remaining near the lower end of its one-month range and significantly below its 20-day moving average.

23 sep 2026, 19:21 UTC

News

BioCryst Pharmaceuticals Inc shares fell as the broader market declines, remaining significantly below the 20-day moving average and near the lower end of its one-month range.

21 sep 2026, 19:35 UTC

BioCryst Pharmaceuticals Inc is trading higher, having reached a peak return earlier in the session, though it remains below its 20-day moving average.

18 sep 2026, 22:25 UTC

BioCryst Pharmaceuticals Inc's stock is trading modestly lower in after-market hours, retracing significantly since Friday's close and positioned near its one-month trading range low.

17 sep 2026, 20:07 UTC

News

BioCryst Pharmaceuticals Inc is advancing during Thursday's session, continuing a positive trend since Wednesday, despite remaining below its 20-day moving average.

16 sep 2026, 22:21 UTC

BioCryst Pharmaceuticals Inc's shares declined modestly in after-market trading, remaining significantly below the 20-day moving average and near the lower end of its one-month range.

15 sep 2026, 20:21 UTC

BioCryst Pharmaceuticals shares are higher in after-market trading, gaining ground despite broader market caution and no specific company news identified.

14 sep 2026, 23:06 UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market hours, recovering from an earlier decline. No specific news was identified to explain the movement.

11 sep 2026, 20:08 UTC

Macro Event

BioCryst Pharmaceuticals Inc is lower today, continuing a seven-session decline amid macroeconomic data showing inflation rates in line with expectations.

10 sep 2026, 23:26 UTC

No specific news was identified for BioCryst Pharmaceuticals Inc. in after-market trading. Shares remained effectively flat since Thursday's close.

9 sep 2026, 23:46 UTC

BioCryst Pharmaceuticals Inc. shares are higher in after-market trading, despite a generally flat performance and remaining below their 20-day moving average.

8 sep 2026, 23:16 UTC

BioCryst Pharmaceuticals shares are higher in after-market hours, despite four consecutive lower closes. No specific news was identified to explain the price movement.

3 sep 2026, 20:07 UTC

BioCryst Pharmaceuticals Inc shares are lower today, continuing a decline since Wednesday. No specific news has been identified to explain the movement.

2 sep 2026, 23:46 UTC

BioCryst Pharmaceuticals Inc shares are lower in after-market hours. No specific news was identified to explain the decline amid broader market sentiment shifts.

1 sep 2026, 22:26 UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market hours following a stable performance. No specific news was identified to explain the price movement.

31 aug 2026, 20:07 UTC

BioCryst Pharmaceuticals Inc shares are lower today amid broader market declines following inflation concerns from the Jackson Hole Economic Symposium.

28 aug 2026, 19:16 UTC

News

BioCryst Pharmaceuticals shares are lower despite reporting Q2 2026 revenue of $218.3 million, reflecting broader market trends and valuation discounts.

27 aug 2026, 20:07 UTC

BioCryst Pharmaceuticals shares are higher as positive jobless claims data boosts market sentiment. The stock stabilized after reaching a session high.

26 aug 2026, 19:36 UTC

Event

BioCryst Pharmaceuticals received marketing approval for ORLADEYO in pediatric patients. Shares are lower today amid broader market trends and inflation data.

24 aug 2026, 19:26 UTC

BioCryst Pharmaceuticals Inc shares are trading higher, maintaining a position above the 20-day moving average and near the midpoint of their one-month range.

21 aug 2026, 22:26 UTC

BioCryst Pharmaceuticals shares moved higher in after-hours trading, reaching a session high before slightly retracing. No specific news was identified to explain the movement.

20 aug 2026, 20:01 UTC

Correlated Moves
Social Media

BioCryst Pharmaceuticals Inc shares are lower amid a decline in the Biotechnology sub-sector. Earlier in the session, shares rebounded from a session high.

19 aug 2026, 23:01 UTC

BioCryst Pharmaceuticals Inc shares are lower in after-market trading, retracing from an earlier uptick with no specific news identified to explain the decline.

18 aug 2026, 20:06 UTC

BioCryst Pharmaceuticals Inc shares are declining amid broader market weakness, with no specific news identified to explain today's price movement.

14 aug 2026, 19:06 UTC

BioCryst Pharmaceuticals is lower today, following broader market concerns over an unexpected drop in U.S. retail sales impacting Federal Reserve interest rate policy.

13 aug 2026, 21:31 UTC

BioCryst Pharmaceuticals shares traded roughly flat in after-market hours, remaining within their one-month range and above the 20-day moving average.

12 aug 2026, 19:41 UTC

BioCryst Pharmaceuticals shares are higher today, rebounding from an earlier dip and reflecting notable volatility during the session. The stock remains above its 20-day moving average.

11 aug 2026, 23:26 UTC

BioCryst Pharmaceuticals Inc shares are lower in after-market hours, reflecting a decline since Tuesday's close amid broader market weakness and cautious sentiment.

10 aug 2026, 19:51 UTC

News

BioCryst Pharmaceuticals Inc. shares are higher after Wall Street Zen upgraded its rating to "strong-buy." Other firms also adjusted price targets amid market uncertainty.

Peer Vergelijking

Prijswijziging

BioCryst Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

135.42% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 20.222 USD  135.42%

Hoogste 32 USD

Laagste 11 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor BioCryst Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

9 ratings

7

Buy

2

Hold

0

Sell

Sentiment

By Acuity

113 / 339 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.